Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiomyopathies

Myocardial fibrosis assessed by CMR to predict events in HCM

Hypertrophic cardiomyopathy is the most common genetic heart disease and is associated with sudden cardiac death and development of heart failure. Risk stratification currently relies only on clinical risk factors, which have low positive predictive value. Myocardial fibrosis, assessed by contrast-enhanced cardiovascular magnetic resonance imaging, may improve risk stratification.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Maron, B. J. et al. for ACC and ESC. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J. Am. Coll. Cardiol. 42, 1687–1713 (2003).

    Article  Google Scholar 

  2. Adabag, A. S. et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 51, 1369–1374 (2008).

    Article  Google Scholar 

  3. Leonardi, S. et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur. Heart J. 30, 2003–2010 (2009).

    Article  Google Scholar 

  4. Maron, M. S. et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ. Heart Fail. 1, 184–191 (2008).

    Article  Google Scholar 

  5. Moon, J. C. et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 41, 1561–1567 (2003).

    Article  Google Scholar 

  6. Rubinshtein, R. et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ. Heart Fail. 3, 51–58 (2010).

    Article  Google Scholar 

  7. Bruder, O. et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2010.05.007.

    Article  Google Scholar 

  8. O'Hanlon, R. et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2010.05.010.

    Article  Google Scholar 

  9. Roes, S. D. et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ. Cardiovasc. Imaging 2, 183–190 (2009).

    Article  Google Scholar 

  10. Flett, A. S. et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122, 138–144 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeroen J. Bax.

Ethics declarations

Competing interests

J. J. Bax has received grants from the following companies: Biotronik, Boston Scientific, Bristol-Myers Squibb Medical Imaging, Edwards Lifesciences, GE Healthcare, Medtronic, St Jude Medical. N. Ajmone Marsan declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ajmone Marsan, N., Bax, J. Myocardial fibrosis assessed by CMR to predict events in HCM. Nat Rev Cardiol 7, 604–606 (2010). https://doi.org/10.1038/nrcardio.2010.137

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.137

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing